Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification

Abstract

Wildtype (WT) gastrointestinal stromal tumors (GISTs), lacking mutations in KIT or PDGFRA, represent 85% of GISTs in pediatric patients. Treatment options for pediatric WT GIST are limited. Recently, expression profiling of a limited number of pediatric and adult WT GISTs and more in depth study of a single pediatric WT GIST implicated the insulin-like growth factor 1 receptor (IGF1R) as a potential therapeutic target in pediatric WT GIST. We performed immunoblotting, SNP and FISH studies to determine the extent of expression, biochemical activation and genomic amplification of IGF1R in a larger number of pediatric WT GISTs. Pediatric WT GISTs expressed IGF1R strongly, whereas typical adult KIT mutant GISTs did not. IGF1R gene amplification was not detected in pediatric WT GISTs, and some KIT-mutant GISTs had IGF1R gene deletion due to monosomy 15. Despite the absence of apparent genomic activation mechanisms accounting for overexpression, clinical study of IGF1R-directed therapies in pediatric WT GIST is warranted.

Figure 1

Western blotting of IGF1R, KIT and AKT shows strong IGF1R expression in pediatric WT GISTs but not in comparison KIT-mutant GISTs.

Figure 2

Copy number at the IGF1R locus as determined by SNP array study (a) and FISH (b and c) of IGF1R (green) and chromosome 15 centromere (red) demonstrates lack of IGF1R gene amplification in pediatric WT GIST.